Why Is NEWAMSTERDAM PHARMA (NAMS) Stock Down Today?

NewAmsterdam Pharma stock is down 6.34% at $29.67 in today’s session. The move follows recent analyst activity and mixed fundamental performance. Despite a recent earnings beat in Q1, the stock has struggled amid a broader decline in revenue and ongoing unprofitability.

What Happened

Jefferies reiterated its stock rating for NewAmsterdam Pharma ahead of key data, but this did not provide immediate support to the stock. Meanwhile, RBC Capital and Guggenheim both recently raised price targets for NAMS, maintaining Outperform and Buy ratings respectively. These actions suggest continued analyst optimism, yet the stock has moved lower. Recent insider transactions show Chief Accounting Officer Louise Frederika Kooij sold shares on two occasions in May and June 2026, with the most recent filing on June 24. These sales totaled $3.5 million in the last 90 days, with no insider purchases recorded.

What The Data Shows

NewAmsterdam Pharma has a market capitalization of $4.1 billion and remains unprofitable, with an EPS of -1.78 over the trailing twelve months. Revenue has declined by 52.1% TTM, and the stock has a low beta of 0.08, indicating minimal volatility relative to the market. The 52-week range is $19.22 to $42.20, and the stock is currently trading near the lower end of that range. The recent earnings beat in Q1, with EPS of -$0.40 and revenue of $3.04 million, was positive but has not translated into sustained momentum.

What To Watch

NewAmsterdam Pharma is not scheduled to report earnings in the near term. Investors should monitor the breadth of analyst coverage and any new data releases that could influence the stock’s trajectory.